Regulation - Vectura


Current filters:


Popular Filters

Two CHMP positives for Novartis


There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

Novartis set to file QVA149 filing in EU and Japan by end of year


Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

Positive outlook for Vectura, as Seebri Breezhaler closer to EU approval


UK-based inhalation product development company Vectura (LSE: VEC) is a step closer to European approval…

FinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

Novartis and Vectura COPD drug candidate NVA237 filed for approval in Japan


The Japanese subsidiary of Swiss drug major Novartis (NOVO: VX) has filed an application for sales and…

Asia-PacificFinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebriVectura

Vectura shares fall as partner Novartis reports US delay for lung cancer drug


Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

Back to top